title: Chitosan nanoparticles reduce LPS-induced inflammatory reaction via inhibition of NF-κB pathway in Caco-2 cells.
abstract: Chitosan nanoparticles (CNP), an extensively oral-administered drug carrier, was investigated for the anti-inflammatory effects on LPS-inflamed Caco-2 cells and the relate mechanisms. CNP could alleviate the decrease of transepithelial electrical resistance (TEER) induced by LPS in Caco-2 monolayer, and significantly inhibit LPS-induced production of TNF-α, MIF, IL-8 and MCP-1 in a dose-dependent manner. PCR array assay revealed that CNP down-regulated the mRNA expression levels of TLR4 in LPS-inflamed Caco-2 cells. CNP was further showed to reduce cytoplasmic IκB-α degradation and nuclear NF-κB p65 levels in LPS-inflamed Caco-2 cells. These results suggested that CNP suppressed LPS-induced inflammatory response by decreasing permeability of intestinal epithelial monolayer and secretion of pro-inflammatory cytokine in Caco-2 cells, which were partially mediated by NF-κB signaling pathway.
authors: Experimental Animal Research Center, Zhejiang Chinese Medical University, PR China. Electronic address: zheyu1114@126.com.
authors: Jue
authors: J
authors: Tu
authors: School of Agriculture and Food Science, Zhejiang A&F University, PR China.
authors: Yinglei
authors: Y
authors: Xu
authors: Experimental Animal Research Center, Zhejiang Chinese Medical University, PR China.
authors: Jianqin
authors: J
authors: Xu
authors: Experimental Animal Research Center, Zhejiang Chinese Medical University, PR China.
authors: Yun
authors: Y
authors: Ling
authors: Experimental Animal Research Center, Zhejiang Chinese Medical University, PR China.
authors: Yueqin
authors: Y
authors: Cai
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D018938:Caco-2 Cells; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000737:chemistry* / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D000072000:NF-KappaB Inhibitor alpha / Q000378:metabolism; D053758:Nanoparticles; D059748:Proteolysis / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects*; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000378:metabolism; D051996:Transcription Factor RelA / Q000378:metabolism*
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D051996:Transcription Factor RelA; D000072000:NF-KappaB Inhibitor alpha; D048271:Chitosan
keywords: Anti-inflammatory effects; Caco-2 cell; Chitosan nanoparticles